Inhibitors of cyclin-dependent kinase 7 (CDK7)

Patent metadata

Field	Value
Publication number	US-10738067-B2
Application number	US-202016787753-A
Country	US
Kind code	B2
Filing date	Feb 11, 2020
Priority date	Nov 1, 2018
Publication date	Aug 11, 2020
Grant date	Aug 11, 2020

Abstract

The present invention provides various compositions, including compounds of Formula (I) or (Ia), or a species thereof, and pharmaceutically acceptable salts, solvates (e.g., hydrates), stereoisomer, tautomers, isotopic and other specified forms thereof. Also provided are methods (or uses) and kits involving the compounds or pharmaceutically acceptable compositions containing them for treating or preventing a disease (e.g., a proliferative disease such as cancer) in a subject. Administration of a compound or pharmaceutical composition described herein is expected to inhibit cyclin-dependent kinase 7 (CDK7), and thereby, induce apoptosis in tumor cells in the subject.

First claim

What is claimed is:

1. A compound of the formula:

2. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2 , wherein the composition is formulated for oral administration.

4. The pharmaceutical composition of claim 3 , wherein the composition is formulated as an aqueous or non-aqueous solution or suspension.

5. The pharmaceutical composition of claim 3 , wherein the composition is formulated as a tablet or capsule.

6. The pharmaceutical composition of claim 2 , wherein the composition is formulated in unit dosage form.

7. The pharmaceutical composition of claim 3 , wherein the composition is formulated in unit dosage form.

8. The pharmaceutical composition of claim 2 , wherein the composition is formulated for administration in liquid form.

9. The pharmaceutical composition of claim 3 , wherein the composition is formulated for administration in liquid form.

10. The pharmaceutical composition of claim 2 , wherein the composition is formulated for administration in solid form.

11. The pharmaceutical composition of claim 3 , wherein the composition is formulated for administration in solid form.

12. The pharmaceutical composition of claim 2 , wherein the pharmaceutically acceptable carrier comprises an inert diluent, a dispersing or granulating agent, a surface active agent or emulsifier, a disintegrating agent, a binding agent, a preservative, a buffering agent, or an emulsifier.

13. The pharmaceutical composition of claim 2 , wherein the pharmaceutically acceptable carrier comprises a cellulose-based substance.

14. The pharmaceutical composition of claim 5 , wherein the carrier comprises lactose and/or corn starch.

15. A pharmaceutically acceptable salt of the compound of claim 1 .

16. The pharmaceutically acceptable salt of claim 15 , wherein the salt is an acid addition salt.

17. The pharmaceutically acceptable salt of claim 16 , wherein the acid addition salt is formed with lactic acid, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, perchloric acid, acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid.

18. A pharmaceutical composition comprising a therapeutically effective amount of the pharmaceutically acceptable salt of claim 15 and a pharmaceutically acceptable carrier.

19. The pharmaceutical composition of claim 18 , wherein the composition is formulated for oral administration.

20. The pharmaceutical composition of claim 19 , wherein the composition is formulated as an aqueous or non-aqueous solution or suspension.

21. The pharmaceutical composition of claim 19 , wherein the composition is formulated as a tablet or capsule.

22. The pharmaceutical composition of claim 18 , wherein the composition is formulated in unit dosage form.

23. The pharmaceutical composition of claim 18 , wherein the pharmaceutically acceptable carrier is a sterile liquid.

24. The pharmaceutical composition of claim 18 , wherein the composition is formulated for administration in liquid form.

25. The pharmaceutical composition of claim 19 , wherein the composition is formulated for administration in liquid form.

26. The pharmaceutical composition of claim 18 , wherein the composition is formulated for administration in solid form.

27. The pharmaceutical composition of claim 19 , wherein the composition is formulated for administration in solid form.

28. The pharmaceutical composition of claim 18 , wherein the pharmaceutically acceptable carrier comprises an inert diluent, a dispersing or granulating agent, a surface active agent or emulsifier, a disintegrating agent, a binding agent, a preservative, a buffering agent, or an emulsifier.

29. The pharmaceutical composition of claim 18 , wherein the pharmaceutically acceptable carrier comprises a cellulose-based substance.

30. The pharmaceutical composition of claim 21 , wherein the carrier comprises lactose and/or corn starch.

Assignees

• Syros Pharmaceuticals Inc

Inventors

• Marineau Jason J
• Bradley Michael
• Chuaqui Claudio Edmundo
• Ciblat Stephane
• Kabro Anzhelika

Classifications

• C07B2200/05

  Isotopically modified compounds, e.g. labelled · CPC title

• A61K31/675

  having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/565

  not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title